Company (symbol)

Date filed

Date comm.

Shares/Units (M)

Price

Shares out (M)

Lead, other underwriters

Gross (US$M)

Post-offering market cap (M)

Initial offerings total: $579.7M

   

Ablynx NV (Ghent, Belgium; ABLX)1

10/4/17

10/26/17

13.13ADS

$17.50

72.8

BofA Merrill Lynch; J.P. Morgan; Jefferies; Baird; Bryan, Garnier & Co.; Ladenburg Thalmann

$230

$1,274.00

Bioarctic AB (Stockholm; Nasdaq Stockholm)2

9/14/17

10/16/17

25S

SEK24

N/A

DNB Markets; Carnegie Investment Bank AB

$74.00

SEK2,560

Optinose Inc. (Yardley, Pa.; OPTN)3

10/13/17

10/19/17

8.625S

$16

36.64

Jefferies; Piper Jaffray; BMO Capital Markets; RBC Capital Markets

$138.00

$586.24

Rhythm Pharmaceuticals Inc. (Boston; RYTM)4

9/5/17

10/6/17

8.1S

$17

27

Morgan Stanley; BofA Merrill Lynch; Cowen & Co.; Needham & Co.

$137.70

$459.00

Number of IPOs in October: 4

Average value of October IPOs: $144.93M

Number of IPOs in 2017: 40

Total raised in IPOs in 2017: $3,902.32M

Average value of IPOs in 2017: $97.56M

Follow-on offerings total: $2,084.27M

   

Abeona Therapeutics Inc. (New York; ABEO)5

7/23/15

10/17/17

5.75S

$16.00

46.04

Jefferies LLC; RBC Capital Markets; Cantor Fitzgerald & Co.; FBR Capital Markets & Co.; H.C. Wainwright & Co.; Jonestrading Institutional Services LLC; Maxim Group LLC

$92.00

$736.64

Ablynx NV (Ghent, Belgium; Brussels:ABLX)6

10/25/17

10/25/17

13.13ADS

$17.50

74.56

BofA Merrill Lynch; J.P. Morgan; Jefferies; Baird; Bryan, Garnier & Co.; Ladenburg Thalmann

$230.00

$1,304.80

Akari Therapeutics plc (London; AKTX)7

8/20/14

10/19/17

3.48ADS

$5.00

1,526

Cantor Fitzgerald & Co.; William Blair & Co. LLC; Canaccord Genuity Inc.

$17.40

$7,630.00

Anaptysbio Inc. (San Diego; ANAB)8

10/11/17

10/12/17

3S

$60.24

23.3

Credit Suisse, Jefferies and Stifel

$180.72

$1,403.59

Atossa Genetics Inc. (Seattle; ATOS)9

10/5/17

10/27/17

11.5S

$0.44

25.52

Maxim Group LLC

$5.10

$11.23

Biotime Inc. (Alameda, Calif.; NYSE MKT:BTX)10

5/5/17

10/13/17

11.04S

$2.60

121.9

Raymond James & Associates; Ladenburg Thalmann; Chardan; Lifesci Capital LLC

$28.80

$316.94

Celsion Corp. (Lawrenceille, N.J.; CLSN)11

9/25/15

10/30/17

2.64S and W for 1.32S

$2.50

10.99

Oppenheimer & Co.

$6.60

$27.48

Corbus Pharmaceuticals Holdings Inc. (Norwood, Mass.; CRBP)12

11/19/15

10/25/17

4.65S

$7.00

54.87

Cantor; JMP Securities; Raymond James

$32.50

$384.09

Eiger Biopharmaceuticals Inc. (Palo Alto, Calif.; EIGR)13

8/4/16

10/30/17

2.13S

$10.00

10.5

BTIG

$21.30

$105.00

Eleven Biotherapeutics Inc. (Cambridge, Mass.; EBIO)14

10/4/17

10/30/17

5.52S, W for 4.47S, and W for 10S

$0.80

N/A

H.C. Wainwright & Co.

$8.00

N/A

Flexion Therapeutics Inc. (Burlington, Mass..; FLXN)15

7/13/17

10/13/17

4.8S

$25.50

36.7

Wells Fargo Securities; BMO Capital Markets; RBC Capital Markets; Needham & Co.; Raymond James

$122.40

$935.85

Hutchison China Meditech Ltd. (London; HCM)16

4/3/17

10/26/17

11.37ADS

$26.50

66.44

BofA Merrill Lynch; Deutsche Bank Securities; Stifel; Canaccord Genuity; Panmure Gordon (U.K.) Ltd.; CITIC CLSA

$301.30

$880.33

Idera Pharmaceuticals Inc. (Cambridge, Mass.; IDRA)17

9/8/17

10/26/17

38.3S

$1.50

188

J.P. Morgan; Goldman Sachs; Barclays; H.C. Wainwright

$57.45

$282.00

Ignyta Inc. (San Diego; RXDX)18

10/18/17

10/20/17

10S

$16.00

66.24

J.P. Morgan Securities LLC; Jefferies LLC; Cantor; Ladenburg Thalmann; Suntrust Robinson Humphrey

$160.00

$1,059.84

Immune Design Corp. (Seattle; IMDZ)19

12/29/15

10/25/17

19.5

$4.10

45.09

Leerink Partners; Cowen; RBC Capital Markets

$79.95

$184.87

Immune Pharmaceuticals Inc. (Englewood Cliffs, N.J.; IMNP)20

10/20/17

10/20/17

Units

$1,000.00

13.68

Maxim Group LLC

$18.00

N/A

Immunogen Inc. (Waltham, Mass.; IMGN)21

5/11/17

10/6/17

16.7S

$6.50

106.27

Jefferies LLC; Leerink Partners; RBC Capital Markets; Canaccord Genuity

$108.40

$690.76

Newlink Genetics Corp. (Ames, Iowa; NLNK)22

7/28/15

10/5/17

5S

$10.25

36.22

BofA Merrill Lynch; Stifel; Baird

$51.25

$371.26

Protagonist Therapeutics Inc. (Newark, Calif.; PTGX)23

10/5/17

10/11/17

3.5S

$17.00

N/A

Leerink Partners LLC; Barclays Capital Inc.; BMO Capital Markets Corp.; Stifel; BTIG LLC; Nomura Securities International Inc.

$60.00

N/A

Rigel Pharmaceuticals Inc. (South San Francisco; RIGL)24

10/5/17

10/6/17

20.8S

$3.35

144.65

Jefferies LLC; BMO Capital Markets; H.C. Wainwright & Co. LLC

$69.70

$484.58

Ritter Pharmaceuticals Inc. (Los Angeles; RTTR)25

9/29/17

10/2/17

Units

N/A

N/A

Aegis Capital Corp.

$23.00

N/A

Strongbridge Biopharma plc (Dublin; SBBP)26

5/8/17

10/5/17

4S

$6.25

39.8

Cantor Fitzgerald & Co.; Oppenheimer & Co. Inc.; H.C. Wainwright & Co.

$25.00

$248.75

Sunesis Pharmaceuticals Inc. (South San Francisco; SNSS)27

6/10/14

10/26/17

7.5S and W for 3.75S; preferred stock

$2; $2,000

31

Cowen; Wells Fargo Securities; Oppenheimer & Co.

$20.00

$62.00

VBI Vaccines Inc. (Cambridge, Mass.; VBIV)28

6/8/17

10/27/17

16.1S

$3.05

63.8

BMO Capital Markets; Canaccord Genuity; Ladenburg Thalmann

$49.10

$194.59

Vical Inc. (San Diego; VICL)29

10/18/17

10/30/17

10S

$2.50

21.55

H.C. Wainwright & Co.

$25.00

$53.88

Vistagen Therapeutics Inc. (South San Francisco; VTGN)30

7/27/17

10/20/17

1.37S and W

$1.75

10.75

Oppenheimer & Co.

$2.40

$18.81

Zogenix Inc. (Emeryville, Calif.; ZGNX)31

10/2/17

10/3/17

7.7S

$37.50

32.5

Leerink Partners; Stifel; Mizuho Securities; JMP Securities; LifeSci Capital

$288.90

$1,218.75

Number of Follow-Ons in October: 27

Average value of October Follow-Ons: $77.2M

Number of Follow-Ons in 2017: 178

Total raised in Follow-Ons in 2017: $19,948M

Average value of Follow-Ons in 2017: $112.07M


Notes

Unless otherwise indicated, shares are traded on the Nasdaq exchange.

This column reflects the shares outstanding following the offering, when disclosed.

Market capitalization is calculated based on the offering price.

Currency conversions are based on exchange rates at the time of the deal.

This chart includes only biotech companies that develop therapeutics.

1 Includes Ablynx's overallotment option: 1.7M new ordinary shares in the form of American depositary shares. Each ADS represents one ordinary share.

2 Bioarctic raised SEK600M (US$74M) in its IPO.

3 Includes Optinose's overallotment option: 1.125M shares.

4 Includes Rhythm's overallotment option: 1.06M shares.

5 Includes Abeona's overallotment option: 750,000 shares.

6 Includes Ablynx's overallotment option: 1.7M ADSs.

7 Akari Therapeutics' overallotment option: 522,000 ADSs.

8 Anaptysbio's overallotment option: 450,000 shares.

9 Atossa Genetics' overallotment option: 1M additional shares of its common stock.

10 Includes Biotime's overallotment option: 1.44M shares.

11 Celsion shares are being sold together with 0.5 warrants, with each whole warrant exercisable to purchase one whole share of common stock. The warrants have an exercise price of $3 per share.

12 Corbus Pharmaceuticals' overallotment option: 697,500 shares.

13 Includes Eiger Biopharmaceuticals' overallotment option: 278,212 additional shares of common stock.

14 Eleven's overallotment option: 1.5M shares and/or warrants for 1.5M shares.

15 Flexion's overallotment option: 720,000 shares.

16 Includes Hutchison China Meditech's overallotment option: 1.48M ADSs. Each ADS represents one half of one ordinary share.

17 Includes Idera Pharmaceuticals' overallotment option: 5M shares.

18 Ignyta's overallotment option: 1.5M shares.

19 Immune Design's overallotment option: 2.925M shares.

20 Immune Pharmaceuticals' units consists of one share of series E convertible preferred stock and 982 warrants, each of which entitles the holder to purchase one share of Immune's common stock. The warrants are initially exercisable at an exercise price of $1.10 per share and expire seven years from the date of issuance.

21 Includes Immunogen's overallotment option: 2.175M shares.

22 Newlink Genetics' overallotment option: 750,000 shares.

23 Protagonist's overallotment option: 529,500 shares.

24 Includes Rigel's overallotment option: 2.7M shares.

25 Ritter's class A units consists of 34.55M shares of common stock and warrants to purchase 34.55M shares; and class B units consisting of 9,180 shares of series A convertible preferred stock. Overallotment option: 8.6M shares and/or warrants to purchase 8.6M shares.

26 Strongbridge's overallotment option: 600,000 shares.

27 Sunesis Pharmaceuticals's offering is for 7.5M shares and warrants to purchase 3.75M shares at a price of $2 each; and 2,500 shares of its non-voting series D convertible preferred stock and warrants to purchase 1.25M shares at a price of $2,000 each.

28 VBI Vaccines also sold 7.47M shares in a concurrent registered direct offering, raising another $22.8M. Public offering includes overallotment option: 2.1M common shares.

29 Vical's overallotment option: 1.5M shares.

30 Vistagen's offering involves 1.37M shares and warrants to purchase up to 1.89M shares.

31 Includes Zogenix's overallotment option: 1M shares.